(Q24241729)

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

Paroxetine controlled release for premenstrual dysphoric disorder: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

Continuous or intermittent dosing with sertraline for patients with severe premenstrual syndrome or premenstrual dysphoric disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

Luteal phase sertraline treatment for premenstrual dysphoric disorder. Results of a double-blind, placebo-controlled, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

Fluoxetine in the treatment of premenstrual syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

Paroxetine Controlled Release for Premenstrual Dysphoric Disorder: Remission Analysis Following a Randomized, Double-Blind, Placebo-Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

Clomipramine effectively reduces premenstrual irritability and dysphoria: a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

Fluvoxamine in the treatment of menstrually related mood disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

Citalopram in PMS patients with prior SSRI treatment failure: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

Fluoxetine treatment of severe premenstrual syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

Recurrence of symptoms of premenstrual dysphoric disorder after the cessation of luteal-phase fluoxetine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

Pretreatment pattern of symptom expression in premenstrual dysphoric disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

Fluoxetine improves functional work capacity in women with premenstrual dysphoric disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

A naturalistic study of paroxetine in premenstrual syndrome: efficacy and side-effects during ten cycles of treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

Paroxetine as a treatment for premenstrual dysphoric disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

Luteal phase treatment of premenstrual dysphoric disorder improves symptoms that continue into the postmenstrual phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

Menstrual cycle phase-related changes in appetite in patients with premenstrual syndrome and in control subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

The relationship between the menstrual cycle and female sexual interest in women with PMS complaints and volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

Characteristics of women seeking treatment for premenstrual syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

Influence of progesterone on serotonin metabolism: a possible causal factor for mood changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

Helping women with premenstrual syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

Platelet monoamine oxidase B activity in women with premenstrual syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

Progesterone metabolite allopregnanolone in women with premenstrual syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

Imipramine receptor binding and serotonin uptake in platelets of women with premenstrual changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

Premenstrual syndromes: overview from a methodologic perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

The efficacy of fluoxetine in improving physical symptoms associated with premenstrual dysphoric disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

Trend analysis of the symptoms of 150 women with a history of the premenstrual syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

7 January 2021

Diagnostic and treatment results from a southeastern academic center-based premenstrual syndrome clinic: the first year

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

7 January 2021

Alteration of platelet serotonergic mechanisms and monoamine oxidase activity in premenstrual syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

7 January 2021

Prevalence of axis I and axis II disorders in women with late luteal phase dysphoric disorder

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

7 January 2021

The serotonin reuptake inhibitor paroxetin is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

7 January 2021

A double-blind trial of four medications to treat severe premenstrual syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

7 January 2021

Buspirone in treatment of premenstrual syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

7 January 2021

Kinetics of citalopram in man; plasma levels in patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

7 January 2021

Fluoxetine in the treatment of premenstrual dysphoria

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

7 January 2021

Blunting of neuroendocrine responses to infusion of L-tryptophan in women with perimenstrual mood change

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

7 January 2021

Placebo-controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

7 January 2021

Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

7 January 2021

Full- or half-cycle treatment of severe premenstrual syndrome with a serotonergic antidepressant

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

7 January 2021

Treatment of premenstrual syndrome with fluoxetine: an open study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

7 January 2021

Open trial of fluoxetine therapy for premenstrual syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

7 January 2021

Symptom-onset treatment for women with premenstrual dysphoric disorder

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

7 January 2021

Serotonin levels and platelet uptake during premenstrual tension

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

7 January 2021

Effects of estradiol on the diurnal rhythm of serotonin activity in microdissected brain areas of ovariectomized rats

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

7 January 2021

Female sexual side effects associated with selective serotonin reuptake inhibitors: a descriptive clinical study of 33 patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

7 January 2021

Serotonin and gender-specific psychiatric disorders

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

7 January 2021

Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

7 January 2021

Predictors of response to sertraline treatment of severe premenstrual syndromes.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

7 January 2021

A preliminary study of luteal phase versus symptom-onset dosing with escitalopram for premenstrual dysphoric disorder.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001396.PUB2

7 January 2021

10.1002/14651858.CD001396.PUB2

Identifiers

DOI

0 references

Fatcat ID

release_m3gkbwjx3fhgjbyoghj5b5ifge

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/m3gkbwjx3fhgjbyoghj5b5ifge

24 November 2022